Oral Health Group
News

Canada Approved Vaccine to Prevent HPV-Related Oropharyngeal and Head and Neck Cancers

April 12, 2022
by Precisions Canada


Quebec-based Merck Canada today announced Health Canada approved an expanded indication of GARDASIL®9 in individuals 9 through 45 years of age to prevent infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58.

And this approval is for Oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.

It is estimated that more than 550,000 Canadians become infected with HPV each year.

View the full story.


See more of the latest dentistry news! 


Print this page

Related


Have your say:

Your email address will not be published.

*